Bioperfectus Technologies

Jiangsu BioPerfectus Technologies Co., Ltd. was founded in 2010 and is located in the high-tech pharmaceutical park—China Medical City in Taizhou, Jiangsu. Bioperfectus Technologies, with molecular diagnostic technology as its core, is a national high-tech enterprise that integrates diagnostic reagents, instruments, and third-party medical testing services to provide comprehensive solutions. The company has become a benchmark enterprise in China's molecular diagnostics industry and was listed on the STAR Market of the Shanghai Stock Exchange on December 5, 2019, with the stock code 688399. The company has two clean production workshops for nucleic acids and proteins that comply with the national medical device production quality management standards and has passed the ISO13485 quality system certification. It possesses talents from the Ministry of Science and Technology's "Innovation and Entrepreneurship" program, Jiangsu Province's "Double Innovation Team," and was selected by the Ministry of Human Resources and Social Security as one of the "Most Growth-Potential Overseas Returnee Entrepreneurial Enterprises" in 2013. In terms of products, the company owns multiple modern biotechnology platforms such as multiplex fluorescent quantitative PCR and enzyme chemistry, engaging in product research, development, production, and sales in areas like disease prevention and control, female reproductive tract microbiome detection, and cancer screening. It has successfully developed nearly 500 products including pathogen detection for infectious diseases, female reproductive tract microbiome detection, and cancer screening. Several products have obtained Class III or Class II product registration certificates issued by the National Medical Products Administration.